News GSK’s ‘bubble baby’ gene therapy passes NICE’s new stricter ... GlaxoSmithKline’s gene therapy Strimvelis for the treatment of the ultra-rare ‘bubble baby syndrome’ has been approved by NICE.
News Orchard’s gene therapy gains UK ‘promising innovative medici... A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
News Alexion price cut opens up Strensiq to more patients Managed access scheme will control costs to NHS.
News Outrage over Duchenne drug price reinflamed by PTC's $35,000... Families affected by the rare muscle wasting disease Duchenne muscular dystrophy will still have to pay a huge premium for Emflaza, a newly-approved drug based on an old steroid that helps
News Alexion appoints former Baxalta chief Hantson as CEO Former AZ chief David Brennan expected to take over as chairman in May.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.